Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.

Molecular cancer therapeutics - 1 Mar 2007

Mitsiades Constantine S, Negri Joseph, McMullan Ciaran, McMillin Douglas W, Sozopoulos Elias, Fanourakis Galinos, Voutsinas Gerassimos, Tseleni-Balafouta Sophia, Poulaki Vassiliki, Batt David, Mitsiades Nicholas

Abstract excerpt

B-Raf is an important mediator of cell proliferation and survival signals transduced via the Ras-Raf-MEK-ERK cascade. BRAF mutations have been detected in several tumors, including papillary thyroid carcinoma, but the precise role of B-Raf as a therapeutic target for thyroid carcinoma is still under investigation. We analyzed a panel of 93 specimens and 14 thyroid carcinoma cell lines for the presence of BRAF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma, Follicular
Share to Carcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Papillary

Share to Carcinoma, Squamous Cell

Share to Extracellular Signal-Regulated MAP Kinases

Share to Isoquinolines

Share to Mitogen-Activated Protein Kinases

Share to Thyroid Neoplasms

Source

Identifiers

PMID: 17363500
DOI: 10.1158/1535-7163.MCT-06-0449

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.PMID 17363500Read ↗

BRAF is a therapeutic target in aggressive thyroid carcinoma.Semantic proximity Read ↗

Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E).Semantic proximity Read ↗

Targeting BRAF in thyroid cancer.Semantic proximity Read ↗

Clinical implications of BRAF mutation in thyroid carcinoma.Semantic proximity Read ↗

BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future PerspectivesSemantic proximity Read ↗

Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas.Semantic proximity Read ↗

Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.Semantic proximity Read ↗

B-RAF V600E mutational analysis of fine needle aspirates correlates with diagnosis of thyroid nodules.Semantic proximity Read ↗

BRAF V600E inhibition in anaplastic thyroid cancer.Semantic proximity Read ↗

Selectively Targeting Mutant BRAF in Thyroid CancerSemantic proximity Read ↗

Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations.Semantic proximity Read ↗

BRAFV600E Mutation Is Associated with Preferential Sensitivity to Mitogen-Activated Protein Kinase Kinase Inhibition in Thyroid Cancer Cell LinesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.